Oligopotent stem cells are a stem cell with limited capacity for differentiation. These cells are capable of supplying their daughter cells with limited lineages. Oligopotent stem cells are identified by their propensity to differentiate into a limited range of cell types, and often easier to isolate from adult tissue sources. Oligopotent stem cells tend to be found in adult tissues, such as bone marrow or the thymus, and they can differentiate into at least one, but usually no more than four, cell types. Examples of cell types that oligopotent stem cells might differentiate into include erythrocytes, leukocytes, platelets, and neurons. Though oligopotent stem cells are not as versatile as pluripotent stem cells, they still provide an important source of new cell types and can be used for various regenerative medicine purposes. One of the main benefits of oligopotent stem cell research and its applications is their usefulness in tissue regeneration and repair, as the oligopotent stem cell types often rely on in the body’s natural healing process. Oligopotent stem cells can be used to regenerate tissue and potentially restore functionality in specific organs or tissue types. Oligopotent stem cells also show promise for their potential to help treat diseases. The stem cells can be genetically modified with desired traits, and used as a treatment for conditions such as cancer and degenerative diseases. Oligopotent stem cells have already been used in clinical trials to restore vision in people living with degenerative vision loss. Finally, oligopotent stem cells have an important role in the scientific research community. First, oligopotent stem cells are a key tool in helping scientists better understand the processes of development, disease, and tissue regeneration. Furthermore, the research done with oligopotent stem cells provide insight into the interaction of stem cells with their environment. This helps scientists develop further understanding of the potential applications of stem cells in various areas of medicine.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States